Compare Synchrony Financial (SYF) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs TransMedics Group Inc — how do they compare? Synchrony Financial trades at $78.37 (market cap $25.53B), while TransMedics Group Inc trades at $87.11 (market cap $3.10B). The key difference: Synchrony Financial is far larger — about 8.2× TransMedics Group Inc's market cap, and Synchrony Financial pays a 1.73% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SYF | TMDX | |
|---|---|---|
Market Cap | $25.53B | $3.10B |
Sector | Financials | Technology |
52-Week High | $88.47 | $150.42 |
52-Week Low | $63.78 | $61.99 |
Dividend Yield | 1.73% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $79.41, up 1.56% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with a P/E of 8.05, net income margin of 23.4%, and consistent earnings beats in recent quarters. Recent Q2 2026 results showed $2.59 EPS, beating estimates by 24.5%, while the CareCredit partnership with Stripe expands financing access for health providers.
SYF presents attractive value with robust capital returns including aggressive buybacks and dividends. Analyst consensus is strongly bullish with a $86.33 price target representing 8.7% upside. Key risks include consumer credit deterioration and rising expenses, but stable purchase volume growth and improved net interest margin outlook support continued earnings growth potential.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
